DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients

Information source: Novartis
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension; Chronic Kidney Disease; Nephrotic Syndrome

Intervention: Valsartan (VAL489) (Drug)

Phase: Phase 1

Status: Completed

Sponsored by: Novartis Pharmaceuticals

Official(s) and/or principal investigator(s):
Novartis Pharmaceuticals, Study Director, Affiliation: Novartis Pharmaceuticals

Summary

This study will assess the pharmacokinetics and safety following single dose of valsartan in Japanese pediatric patients with hypertension, chronic kidney disease, or nephrotic syndrome.

Clinical Details

Official title: A Multicenter, Open-label, Single-dose Study to Evaluate the Pharmacokinetics of Valsartan in Japanese Pediatric Patients 6 to 14 Years of Age

Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Primary outcome:

AUC of valsartan in plasma

Cmax of valsartan in plasma

Tmax of valsartan in plasma

T1/2 of valsartan in plasma

CL/F of valsartan in plasma

Secondary outcome:

ECG evaluations

Standard clinical laboratory evaluations

Vital signs

Physical examination

Number and severity of adverse events

Eligibility

Minimum age: 6 Years. Maximum age: 14 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Japanese pediatric patients with hypertension, chronic kidney disease, or nephrotic

syndrome Exclusion Criteria:

- GFR < 30 mL/min/1. 73 m2

- Inability to safely tolerate the temporary discontinuation of concomitant

antihypertensive medications (expect amlodipine or atenolol) from 24 hours prior to study drug administration to study completion.

- Inability to safely tolerate the temporary discontinuation of any drug known or

suspected to effect hepatic or renal clearance capacity from 24 hours prior to study drug administration to study completion (this includes drugs that are known to cause induction or inhibition of hepatic enzymes). Other protocol-defined inclusion/exclusion criteria may apply

Locations and Contacts

Novartis Investigative Site, Aichi, Japan

Novartis Investigative Site, Tokyo, Japan

Additional Information

Starting date: August 2011
Last updated: May 6, 2012

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017